Document is current
Any future updates will be listed below
-
Authors
Rehman, Aqeeb Ur https://orcid.org/0000-0002-3795-8998
Ayoobkhan, Fathima Shehnaz
Shahzad, Moazzam https://orcid.org/0000-0002-9609-6160
Amin, Muhammad Kashif
Shatnawi, Sara
Irfan, Sohaib
Chaudhary, Sibgha Gull
Anwer, Faiz https://orcid.org/0000-0001-6914-7439
McGuirk, Joseph P. https://orcid.org/0000-0002-0539-4796
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
Ahmed, Nausheen https://orcid.org/0000-0003-4336-4982
Abdallah, Al-Ola https://orcid.org/0000-0002-6603-185X
Mushtaq, Muhammad Umair https://orcid.org/0000-0001-8122-0563
- License Information
-
More Information
Article History
Received: 19 December 2024
Revised: 3 April 2025
Accepted: 10 April 2025
First Online: 5 May 2025
Competing interests
: MUM has research funding from Iovance Biotherapeutics for an investigator-initiated trial outside of this work. NA has an advisory role in Bristol Myers Squibb and a consulting role with Kite/Gilead. JPM has consulting and advisory roles in Bristol Myers Squibb, Kite, Novartis, AlloVir, Envision, Autolus, Nektar Therapeutics, CRISPR Therapeutics, Caribou Bio, Sana Technologies, Legend Biotech, and Cargo Therapeutics. The remaining authors declare that no other commercial or financial relationships could be construed as potential conflicts of interest. FA served as advisor and speaker for Bristol Myers Squibb, Celgene, Caribou biosciences, GI Innovation and Poseida Therapeutics; received research funding from Allogene Therapeutic, Celgene, GlaxoSmithKline, Bristol Myers Squibb, and Cariou Biosciences.
